BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Follow-Up Questions
Who is the CEO of BioCryst Pharmaceuticals Inc?
Mr. Jon Stonehouse is the President of BioCryst Pharmaceuticals Inc, joining the firm since 2007.
What is the price performance of BCRX stock?
The current price of BCRX is $6.7, it has decreased 2.25% in the last trading day.
What are the primary business themes or industries for BioCryst Pharmaceuticals Inc?
BioCryst Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is BioCryst Pharmaceuticals Inc market cap?
BioCryst Pharmaceuticals Inc's current market cap is $1.4B
Is BioCryst Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 14 analysts have made analyst ratings for BioCryst Pharmaceuticals Inc, including 5 strong buy, 11 buy, 2 hold, 0 sell, and 5 strong sell
